Physician profile
Jason Black
NPI 1306013305
$995.18
in general payments reported to CMS, 2019-2025
22 companies · $835 in 2025
The $835 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $54.11 · 2023: $32.14 · 2024: $74.27 · 2025: $835.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $941.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $941.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $158.63 | 2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $122.78 | 2025 | Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $119.06 | 2023-2025 | |
| Astellas Pharma US INC | $84.00 | 2023-2025 | Veozah |
| Abbvie INC. | $59.80 | 2021-2025 | |
| Lilly USA, LLC | $59.62 | 2025 | Kisunla, Zepbound, Mounjaro |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $49.31 | 2025 | Caplyta |
| Boston Scientific Corporation | $41.29 | 2024 | Wavewriter Alpha Prime 16 |
| Otsuka America Pharmaceutical, INC. | $36.80 | 2025 | Rexulti |
| Novo Nordisk INC | $35.93 | 2025 | Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.97 | 2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $27.22 | 2025 | Spravato |
| Sumitomo Pharma America, INC. | $23.50 | 2025 | Gemtesa |
| Axsome Therapeutics, INC. | $20.64 | 2025 | Auvelity |
| Exact Sciences Corporation | $17.25 | 2025 | Cologuard Collection Kit |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $16.75 | 2025 | Zenpep |
| Phathom Pharmaceuticals, INC. | $16.75 | 2025 | Voquezna |
| Azurity Pharmaceuticals, INC. | $15.97 | 2025 | Edarbi |
| Amgen INC. | $15.87 | 2024 | Otezla, Repatha |
| Novartis Pharmaceuticals Corporation | $15.02 | 2025 | |
| Sanofi-Aventis U.S. LLC | $14.20 | 2025 | |
| Pfizer INC. | $11.82 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Black listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.